Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., . . . Guigay, J. (2017). Impact of nivolumab vs standard, single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: Health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial. Lancet Oncol.
Stile di citazione ChicagoHarrington, Kevin J., et al. "Impact of Nivolumab Vs Standard, Single-agent Therapy of Investigator’s Choice On Patient-reported Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Health-related Quality-of-life Results From CheckMate 141, a Randomized, Phase 3 Trial." Lancet Oncol 2017.
Citazione MLAHarrington, Kevin J., et al. "Impact of Nivolumab Vs Standard, Single-agent Therapy of Investigator’s Choice On Patient-reported Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Health-related Quality-of-life Results From CheckMate 141, a Randomized, Phase 3 Trial." Lancet Oncol 2017.